非蘇拉贊(英語:Fexuprazan,商品名Fexuclue,分子式:C19H17F3N2O3S)是一種治療胃食道逆流病的藥物,[1]它是一種鉀離子競爭性酸阻滯劑英語potassium-competitive acid blocker[2]

非蘇拉贊
臨床資料
商品名英語Drug nomenclatureFexuclue
其他名稱Abeprazan; DWP14012; DWP-14012
法律規範狀態
法律規範
  • Rx in South Korea, Mexico
識別資訊
  • 1-[5-(2,4-Difluorophenyl)-1-(3-fluorophenyl)sulfonyl-4-methoxypyrrol-3-yl]-N-methylmethanamine
CAS號1902954-60-2
PubChem CID
DrugBank
ChemSpider
UNII
ChEMBL
化學資訊
化學式C19H17F3N2O3S
摩爾質量410.41 g·mol−1
3D模型(JSmol英語JSmol
  • CNCC1=CN(C(=C1OC)C2=C(C=C(C=C2)F)F)S(=O)(=O)C3=CC=CC(=C3)F
  • InChI=1S/C19H17F3N2O3S/c1-23-10-12-11-24(28(25,26)15-5-3-4-13(20)8-15)18(19(12)27-2)16-7-6-14(21)9-17(16)22/h3-9,11,23H,10H2,1-2H3
  • Key:OUNXGNDVWVPCOL-UHFFFAOYSA-N

它在韓國和墨西哥已獲批使用。[3][4]

參考文獻

編輯
  1. ^ Ramani, Azaan; Merchant, Alisha; Cash, Brooks D. Review of the clinical development of fexuprazan for gastroesophageal reflux–related disease. European Journal of Clinical Pharmacology. 2023, 79 (8): 1023–1029. PMID 37344679. S2CID 259222741. doi:10.1007/s00228-023-03521-4. 
  2. ^ Kim, Gwang Ha; Choi, Myung-Gyu; Kim, Jin Il; Lee, Soo Teik; Chun, Hoon Jai; Lee, Kook Lae; Choi, Suk Chei; Jang, Jae-Young; Lee, Yong Chan; Kim, Jae Gyu; Kim, Ki Bae; Shim, Ki-Nam; Sohn, Chong Il; Kim, Sung Kook; Kim, Sang Gyun; Jang, Jin Seok; Kim, Nayoung; Jung, Hwoon-Yong; Park, Hyojin; Huh, Kyu Chan; Lee, Kwang Jae; Hong, Su Jin; Baek, Song; Han, Jin Joo; Lee, Oh Young. Efficacy and Safety of Fexuprazan in Patients with Acute or Chronic Gastritis. Gut and Liver. 2023, 17 (6): 884–893. PMC 10651377 . PMID 36789577. doi:10.5009/gnl220457. 
  3. ^ 펙수클루정40밀리그램(펙수프라잔염산염). nedrug.mfds.go.kr. 
  4. ^ Daewoong Pharma's GER drug gets product OK from Mexico. Korea Economic Daily. October 19, 2023 [2023-11-30]. (原始內容存檔於2023-11-28).